The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 2, 2007, Pages 249-251

  Eron Jr , Joseph J ^a   Bosch, Ronald J ^b   Bettendorf, Daniel ^b   Petch, Leslie ^a   Fiscus, Susan ^a   Frank, Ian ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; LAMIVUDINE; METHIONINE; VALINE; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CODON; CROSS RESISTANCE; DNA SEQUENCE; DRUG ACTIVATION; DRUG EFFECT; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFECTION SENSITIVITY; LETTER; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; POINT MUTATION;

EID: 34249870121     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318050d61f     Document Type: Letter

References (7)

1. Gu Z, Gao Q, Li X, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol. 1992;66:7128-7135.
2. Winters MA, Bosch RJ, Albrecht MA, et al. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J Infect Dis. 2003;188:537-540.
3. Molina JM, Marcelin AG, Pavie J, et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005;191:840-847.
4. Frank I, Bosch RJ, Fiscus S, et al. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses. 2004;20:916-926.
5. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med. 2000;19:3171-3191.
6. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
7. Flandre P, Chappey C, Marcelin AG, et al. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. J Infect Dis. 2007;195:392-398.